Denise Scots-Knight

Dr. Denise V.
Scots-Knight is a President at Mereo BioPharma 5, Inc., an Independent Director at Elanco Animal Health, Inc. and a Chief Executive Officer & Director at Mereo BioPharma Group Plc.
She is on the Board of Directors at Elanco Animal Health, Inc., Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd., Mereo BioPharma 3 Ltd. and Mereo BioPharma 4 Ltd. Dr. Scots-Knight was previously employed as a Managing Partner by Phase4 Partners Ltd., a Managing Partner by Phase4 Partners Ltd., an Independent Director by Albireo Pharma, Inc., a Chairman-Supervisory Board by Nabriva Therapeutics GmbH, a Trustee by British Heart Foundation, an Independent Director by Idenix Pharmaceuticals LLC, a Managing Director by Nomura International Plc, and a Member by Rothschild Asset Management Ltd. She also served on the board at Albireo Ltd., Albireo AB, Cerimon Pharmaceuticals, Inc., DeveloGen AG and ViaCell, Inc. She received her undergraduate degree from the University of California, Berkeley, an undergraduate degree from the University of Birmingham and a doctorate degree from the University of Birmingham.